Stock Track | Akebia Therapeutics Soars 5.48% as Analysts Reaffirm Buy Ratings

Stock Track
08/08

Akebia Therapeutics (AKBA) stock is soaring 5.48% in pre-market trading on Friday, buoyed by positive analyst ratings from two prominent firms. The biotechnology company, which focuses on developing and commercializing therapeutics for patients with kidney disease, is seeing increased investor interest following these bullish assessments.

Piper Sandler analyst Allison Bratzel has maintained a Buy rating on Akebia Therapeutics, setting a price target of $6.00. This target represents significant upside potential from the stock's current trading levels. Similarly, H.C. Wainwright analyst Matthew Caufield has reiterated a Buy rating on the company, with an even more optimistic price target of $8.00.

These reaffirmed Buy ratings from respected financial institutions suggest strong confidence in Akebia Therapeutics' business model and growth prospects. Investors appear to be responding positively to these analyst endorsements, driving the stock's pre-market surge. As the market opens, all eyes will be on Akebia Therapeutics to see if this upward momentum continues throughout the trading session.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10